Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
92 hedge funds and large institutions have $108M invested in Seelos Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 15 closing their positions.
213% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 15
53% more funds holding
Funds holding: 60 → 92 (+32)
39% more call options, than puts
Call options by funds: $1.97M | Put options by funds: $1.42M
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
14% less capital invested
Capital invested by funds: $125M → $108M (-$17.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$9.99M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.04M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$7.85M |
| 5 |
Two Sigma Investments
New York
|
+$7.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$14.7M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$7.22M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$3.05M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.04M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$2.2M |
SEEL Hedge Fund Activity: Q2 2021 in Review
92 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2021, worth a combined $108M — down 14% from $125M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new SEEL positions and 15 closed out — a net gain of 32 holders — while 22 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $17.7M. The largest seller was Invesco, cutting an estimated $14.7M.
- 92 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2021, up from 60 in Q1 2021.
- Funds reported $108M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2021, down 14% quarter-over-quarter.
- 47 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2021 and 15 closed out, a net change of +32 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $17.7M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2021 was Invesco, an estimated $14.7M sold.
Based on aggregated 13F filings for Q2 2021.